Biological impact of iberdomide in patients with active systemic lupus erythematosus
Peter E. Lipsky(Ampel BioSolutions (United States)), Peter Schäfer(Bristol-Myers Squibb (United States)), Ronald van Vollenhoven(Amsterdam University Medical Centers), Benito Velasco Zamora, Michael Weiswasser(Bristol-Myers Squibb (United States)), Robert Gagnon(Bristol-Myers Squibb (United States)), Allison Gaudy(University of Rochester Medical Center), Maria Majdan(Medical University of Lublin), Victoria P. Werth(Philadelphia VA Medical Center), Nikolay Delev(Bristol-Myers Squibb (Sweden)), Fedra Irazoque-Palazuelos, Joan T. Merrill(Oklahoma Medical Research Foundation), Mark Stern(Bristol-Myers Squibb (United States)), Shimon Korish(Bristol-Myers Squibb (United States)), Robert Terbrueggen(California State University, Dominguez Hills), Milan Petronijević(Military Medical Academy), Richard Furie(Hofstra University), Thomas Dörner(German Rheumatism Research Centre), Ying Ye(Dalian Medical University), Zhaohui Liu(University of Maryland, Baltimore), Sarah Hersey(Bristol-Myers Squibb (United States)), Shaojun Tang(Boston Children's Hospital)
Cited by 37
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
|New England Journal of Medicine|2005|1.1k